Manning Paul B made notable open market purchases of biotech stocks over the last year, including 17.5 million dollars in Verrica Pharmaceuticals ($VRCA) across two transactions, with the latest on November 25, 2025, ranking him 67th among 4,983 individual insiders (average purchase: 1.5 million dollars over 3.3 trades). He also bought 2.1 million dollars of Taysha Gene Therapies ($TSHA) on May 30, 2025 (302nd rank) and 3 million dollars of Candel Therapeutics ($CADL) on February 23, 2026 (242nd rank). On the sell side, he offloaded 19 million dollars of Liquidia Corp ($LQDA) in four trades, most recently on September 2, 2025, placing 709th among 11,678 insiders (average sale: 8.6 million dollars over 6.4 trades).
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 31, 2026 | Candel Therapeutics, Inc. | $CADL | Manning Paul B | Not found | A | Stock Option (Right to Buy) | 4618 | $4.11 | 4,618.0000 | 55,018,457 | 9999.99% | 0.01% |
| Feb. 23, 2026 | Candel Therapeutics, Inc. | $CADL | Manning Paul B | Not found | P | Common Stock | 550458 | $5.45 | 5,748,279.0000 | 55,018,457 | 10.59% | 1.00% |
| Feb. 11, 2026 | Liquidia Corp | $LQDA | Manning Paul B | Not found | J | Common Stock | 55116 | $42.63 | 5,950,110.0000 | 86,059,101 | 0.92% | 0.06% |
| Feb. 11, 2026 | Liquidia Corp | $LQDA | Manning Paul B | Not found | J | Common Stock | 55116 | $42.63 | 5,950,110.0000 | 86,059,101 | 0.93% | 0.06% |
| Nov. 25, 2025 | Verrica Pharmaceuticals Inc. | $VRCA | Manning Paul B | Not found | P | Series C Warrant (right to buy) | 343845 | $0.00 | 1,031,535.0000 | 9,490,035 | 50.00% | 3.62% |
| Nov. 25, 2025 | Verrica Pharmaceuticals Inc. | $VRCA | Manning Paul B | Not found | P | Common Stock | 1375380 | $4.24 | 7,932,218.0000 | 9,490,035 | 20.98% | 14.49% |
| Nov. 25, 2025 | Verrica Pharmaceuticals Inc. | $VRCA | Manning Paul B | Not found | P | Series C Warrant (right to buy) | 687690 | $0.00 | 1,031,535.0000 | 9,490,035 | 200.00% | 7.25% |
| Nov. 25, 2025 | Verrica Pharmaceuticals Inc. | $VRCA | Manning Paul B | Not found | P | Common Stock | 2750762 | $4.24 | 7,932,218.0000 | 9,490,035 | 53.09% | 28.99% |
| Aug. 29, 2025 | Liquidia Corp | $LQDA | Manning Paul B | Not found | S | Common Stock | 188232 | $27.62 | 6,278,378.0000 | 85,588,108 | 2.91% | 0.22% |
| Aug. 28, 2025 | Liquidia Corp | $LQDA | Manning Paul B | Not found | S | Common Stock | 154337 | $27.94 | 6,466,610.0000 | 85,588,108 | 2.33% | 0.18% |
| Sept. 2, 2025 | Liquidia Corp | $LQDA | Manning Paul B | Not found | S | Common Stock | 74230 | $29.14 | 5,950,110.0000 | 85,588,108 | 1.23% | 0.09% |
| Sept. 2, 2025 | Liquidia Corp | $LQDA | Manning Paul B | Not found | S | Common Stock | 254038 | $28.67 | 6,024,340.0000 | 85,588,108 | 4.05% | 0.30% |
| June 25, 2025 | Candel Therapeutics, Inc. | $CADL | Manning Paul B | Not found | A | Common Stock | 1070663 | $4.67 | 5,197,821.0000 | 46,933,088 | 25.94% | 2.28% |
| June 17, 2025 | Liquidia Corp | $LQDA | Manning Paul B | Director | A | Common Stock | 18396 | $0.00 | 6,620,947.0000 | 85,172,696 | 0.28% | 0.02% |
| June 17, 2025 | Candel Therapeutics, Inc. | $CADL | Manning Paul B | Not found | A | Stock Option (Right to Buy) | 14240 | $0.00 | 14,240.0000 | 46,933,088 | 9999.99% | 0.03% |
| May 30, 2025 | Taysha Gene Therapies, Inc. | $TSHA | Manning Paul B | Not found | P | Common Stock | 750000 | $2.75 | 25,601,111.0000 | 250,134,421 | 3.02% | 0.30% |
| Dec. 16, 2024 | Candel Therapeutics, Inc. | $CADL | Manning Paul B | Not found | P | Common Stock | 500000 | $6.00 | 4,127,158.0000 | 32,247,744 | 13.78% | 1.55% |
| Dec. 16, 2024 | Candel Therapeutics, Inc. | $CADL | Manning Paul B | Not found | P | Common Stock | 750000 | $6.00 | 4,127,158.0000 | 32,247,744 | 22.21% | 2.33% |
| Nov. 22, 2024 | Verrica Pharmaceuticals Inc. | $VRCA | Manning Paul B | Not found | P | Common Stock | 18426966 | $0.00 | 38,510,779.0000 | 0 | 91.75% | 0.00% |
| Nov. 22, 2024 | Verrica Pharmaceuticals Inc. | $VRCA | Manning Paul B | Not found | P | Common Stock | 4494382 | $0.00 | 38,060,779.0000 | 0 | 13.39% | 0.00% |
| Nov. 26, 2024 | Verrica Pharmaceuticals Inc. | $VRCA | Manning Paul B | Not found | G | Common Stock | 450000 | $0.00 | 38,060,779.0000 | 0 | 1.17% | 0.00% |
| Nov. 22, 2024 | Verrica Pharmaceuticals Inc. | $VRCA | Manning Paul B | Not found | P | Series A Warrants (right to buy) | 9213483 | $0.00 | 11,460,674.0000 | 0 | 410.00% | 0.00% |
| Nov. 22, 2024 | Verrica Pharmaceuticals Inc. | $VRCA | Manning Paul B | Not found | P | Series B Warrants (right to buy) | 9213483 | $0.00 | 11,460,674.0000 | 0 | 410.00% | 0.00% |
| Nov. 22, 2024 | Verrica Pharmaceuticals Inc. | $VRCA | Manning Paul B | Not found | P | Series A Warrants (right to buy) | 2247191 | $0.00 | 11,460,674.0000 | 0 | 24.39% | 0.00% |
| Nov. 22, 2024 | Verrica Pharmaceuticals Inc. | $VRCA | Manning Paul B | Not found | P | Series B Warrants (right to buy) | 2247191 | $0.00 | 11,460,674.0000 | 0 | 24.39% | 0.00% |
| Sept. 19, 2024 | Verrica Pharmaceuticals Inc. | $VRCA | Manning Paul B | Not found | G | Common Stock | 891870 | $0.00 | 13,805,690.1700 | 0 | 6.91% | 0.00% |
| Sept. 19, 2024 | Verrica Pharmaceuticals Inc. | $VRCA | Manning Paul B | Not found | G | Common Stock | 2675611 | $0.00 | 13,805,690.1700 | 0 | 16.23% | 0.00% |
| Sept. 19, 2024 | Verrica Pharmaceuticals Inc. | $VRCA | Manning Paul B | Not found | G | Common Stock | 891870 | $0.00 | 13,805,690.1600 | 0 | 6.91% | 0.00% |
| Sept. 19, 2024 | Verrica Pharmaceuticals Inc. | $VRCA | Manning Paul B | Not found | G | Common Stock | 891870 | $0.00 | 13,805,690.1700 | 0 | 6.91% | 0.00% |
| Sept. 12, 2024 | Liquidia Corp | $LQDA | Manning Paul B | Director | P | Common Stock | 337078 | $8.90 | 6,602,551.0000 | 76,435,831 | 5.38% | 0.44% |
| June 27, 2024 | Taysha Gene Therapies, Inc. | $TSHA | Manning Paul B | Not found | P | Common Stock | 1333333 | $2.25 | 24,851,111.0000 | 116,121,482 | 5.67% | 1.15% |
| June 26, 2024 | Candel Therapeutics, Inc. | $CADL | Manning Paul B | Not found | A | Stock Option (Right to Buy) | 14240 | $0.00 | 14,240.0000 | 29,213,627 | 9999.99% | 0.05% |
| June 20, 2024 | Liquidia Corp | $LQDA | Manning Paul B | Director | A | Common Stock | 20359 | $0.00 | 6,265,473.0000 | 75,393,907 | 0.33% | 0.03% |
| Dec. 14, 2023 | Liquidia Corp | $LQDA | Manning Paul B | Director | P | Common Stock | 279330 | $7.16 | 6,245,114.0000 | 64,857,508 | 4.68% | 0.43% |
| June 19, 2023 | Liquidia Corp | $LQDA | Manning Paul B | Director | A | Non-Qualified Stock Option (right to buy) | 20000 | $0.00 | 20,000.0000 | 64,656,424 | 9999.99% | 0.03% |